Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2023-05-01
2027-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Therapy(FT-003) for Wet AMD
NCT06492863
Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
NCT02868424
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
NCT05297292
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
NCT05099094
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
NCT05858983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FT003 Dose 1
Low dose of FT-003
FT-003
Administered via intraocular injection.
FT003 Dose 2
Mid dose of FT-003
FT-003
Administered via intraocular injection.
FT003 Dose 3
High dose of FT-003
FT-003
Administered via intraocular injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FT-003
Administered via intraocular injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female or male patients ≥45 years old at the time of signing the ICF;
* Clinically diagnosed with nAMD;
* Presence of active CNV
* The best corrected visual acuity (BCVA) of the studied eye is ≤ 53 letters;
Exclusion Criteria
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Soochow University
OTHER
Tianjin Medical University Eye Hospital
OTHER
Peking Union Medical College Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Frontera Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peirong Lu, Professor
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Soochou University
Xiaorong Li, Professor
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Eye Hospital
Hanyi Min
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Guangming Wan
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FT003WA-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.